Skip to main content

NOTICE: Due to a lapse in annual appropriations, most of this website is not being updated. Learn more.

Form submissions will still be accepted but will not receive responses at this time. Sections of this site for programs using non-appropriated funds (such as NVLAP) or those that are excepted from the shutdown (such as CHIPS and NVD) will continue to be updated.

U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Cell Manufacturing Consortium

Goal: Establish a collaborative public-private partnership that engages industry, academia, regulators, and other stakeholders in removing barriers to the advancement of the cell-manufacturing industry, thereby bringing new therapies and diagnostics to the healthcare market.

Lead: Georgia Research Alliance
191 Peachtree Street, NE, Suite 849
Atlanta, GA 30303-1740

Award Number: 70NANB14H048

Federal Funding: $499,636

Project Duration: 18 months

Joined by nine founding partners, the Georgia Research Alliance will:

  • Create a national consortium in the promising but nascent field of cell manufacturing,
  • Identify and prioritize current technical challenges impeding progress,
  • Create a clear roadmap that integrates research with development of commercially viable manufacturing processes,
  • Identify future research directions and potential novel technologies to advance the cell manufacturing industry, and
  • Develop mechanisms for addressing future needs for cell therapies and diagnostics.

Today, the market for cell-based medical technologies, such as antibodies and vaccines, tops $1 billion.In prospect are therapies that could improve the lives of patients with variety of serious diseases and conditions that are incurable today. These range from reversing paralysis caused by spinal-cord injuries to combating heart failure, to treating auto-immune diseases and cancer. Other anticipated uses include screening platforms for predictive and personalized medicine. Because of the many envisioned applications and predicted health benefits, the global market for cell-based medical technologies is expected to multiply several times over. However, cost-effective, large-scale manufacturing—or bioprocessing—capabilities necessary to produce these emerging therapies and diagnostic tools are lacking. This new consortium aims to position the United States as the leading developer of cell-manufacturing technologies and the chief authority on cell manufacturing standards, worldwide.

For project information: Amanda Schroeder, (404) 332-9770, ASchroeder [at] gra.org (ASchroeder[at]gra[dot]org)

Funded Partners:

  • Aruna Biomedical (Athens, Ga.)
  • Celgene Cellular Therapeutics (Warren, N.J.)
  • Cellular Dynamics International, Inc. (Madison, Wis.)
  • Georgia Institute of Technology (Atlanta, Ga.)
  • North Carolina State University (Raleigh, N.C.)
  • RoosterBio (Frederick, Md.)
  • University of California Berkeley (Berkeley, Calif.)
  • University of Georgia (Athens, Ga.)
  • University of Wisconsin (Madison, Wis.)

AMTech Project Manager: Jean-Louis Staudenmann, (301) 975-4866, jean-louis.staudenmann [at] nist.gov (jean-louis[dot]staudenmann[at]nist[dot]gov)

Created May 6, 2014, Updated April 10, 2019
Was this page helpful?